Reaction
Acanthamoeba Infection reporting signals
As of the last recalculation, Acanthamoeba Infection appears in 188 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is POSACONAZOLE DELAYED-RELEASE (PRR 264.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Posaconazole Delayed-Release | 23 | 264.1 | 264.6 |
| Atovaquone | 17 | 256.9 | 257.5 |
| Ganciclovir | 16 | 189.1 | 189.4 |
| Ganciclovir Sodium | 16 | 182.9 | 183.1 |
| Posaconazole | 23 | 178.4 | 178.7 |
| Tacrolimus Ointment 0.1% | 90 | 152.6 | 152.7 |
| Tacrolimus Extended-Release Capsules | 90 | 152.2 | 152.3 |
| Tacrolimus | 96 | 137.6 | 137.7 |
| Alemtuzumab | 20 | 128.0 | 128.1 |
| Mycophenilic Acid | 20 | 119.5 | 119.6 |
| Voriconazole Injection | 18 | 101.4 | 101.5 |
| Brentuximab Vedotin | 8 | 90.2 | 90.3 |
| Busulfan | 12 | 90.1 | 90.2 |
| Bleomycin Sulfate | 8 | 89.5 | 89.6 |
| Voriconazole | 18 | 72.4 | 72.5 |